Obesity Management
60 articles on Obesity Management, researched and written by the Shotlee Editorial Team from primary sources.
New “Trojan Horse” Drug Supercharges Weight Loss in Early Trials
A new hybrid molecule designed by Helmholtz Munich researchers acts as a Trojan horse to deliver metabolic compounds directly into cells, showing superior weight loss in mice compared to standard treatments.
8 min read
Eli Lilly to Seek FDA Approval for Obesity Drug Retatrutide
Eli Lilly announces plans to file for FDA approval of its triple-agonist obesity drug retatrutide in early 2027 following successful Phase 3 trial data.
8 min read
The New Drug Melting Body Fat From 38% To 22% — And The Side Effects Patients Are Ignoring
A detailed look at the case of Gary Anderton, who achieved significant weight loss using unregulated peptides, and the critical safety risks associated with this trend.
8 min read
GLP-1s for Teen Weight Loss: A New Treatment Trend?
GLP-1 medications are rapidly changing obesity care for teens and young adults, with a notable shift away from bariatric surgery. This article delves into the latest research, potential benefits, and important considerations for this emerging trend.
7 min read
Medicare's New GLP-1 Weight-Loss Drug Program: What to Know
Medicare is launching a new pilot program to increase access to GLP-1 medications for weight loss, offering a $50 monthly copay for eligible beneficiaries. This marks a significant step in covering obesity as a medical condition.
9 min read
Plus-Size Swimsuit Model on Inclusivity Amidst GLP-1 Medications
Plus-size model Hunter McGrady shares her concerns about a perceived decline in fashion inclusivity, particularly in the context of the growing popularity of GLP-1 weight loss medications.
7 min read
Dr. Oz Links Obesity to Chronic Disease Surge, Suggests GLP-1s Can 'Jumpstart' Better Health
CMS Administrator Dr. Oz highlights the critical link between obesity and chronic diseases, advocating for the strategic use of GLP-1 medications to improve health and potentially cut healthcare costs.
7 min read
GLP-1 Weight-Loss Drugs Linked to Lower Risks of Addiction and Overdose
Explore the groundbreaking research linking GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, to a reduced risk of substance use disorders and fewer addiction-related emergencies.
8 min read
Bariatric Surgery Shows 5x More Weight Loss Than GLP-1s in Real-World Study
A groundbreaking real-world comparison study presented at the ASMBS 2025 Annual Scientific Meeting found that bariatric surgery resulted in approximately five times more weight loss compared to popular GLP-1 receptor agonist medications over a two-year period. This research highlights important considerations for patients and healthcare providers navigating weight management options.
7 min read
GLP-1 Medications for Obesity: Experts See a Broader Revolution Ahead
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
6 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Navigating Medicare's New Path for GLP-1 Weight Loss Coverage
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
6 min read
Mounjaro Access Expands: Northern Ireland Launches New Weight Loss Service
Northern Ireland is set to launch a £5 million Regional Obesity Management Service, improving access to Mounjaro and lifestyle support for adults struggling with obesity.
8 min read
Ozempic, Wegovy & Mounjaro: How GLP-1s Are Reshaping the Diet Industry
The landscape of weight loss and diet trends is undergoing a seismic shift, largely driven by the widespread adoption of GLP-1 receptor agonists. From Ozempic to Wegovy and Mounjaro, these medications are not just changing how individuals manage their weight but are fundamentally altering the food industry and the very concept of dieting.
7 min read
Beyond Weight Loss: The Next Wave of GLP-1 Drugs
The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.
7 min read
Oral Wegovy's Record-Breaking Launch: The New Era of Needle-Free Weight Loss
Novo Nordisk's Wegovy oral formulation has achieved unprecedented prescription rates, marking a pivotal shift in obesity care and intensifying competition with Eli Lilly.
8 min read
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
7 min read
Wegovy and Zepbound on Medicare: What the $50 Co-Pay Means for Your Health
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
7 min read
Beyond the Needle: New Oral Semaglutide Tech Could Change Weight Loss Forever
Duke University researchers have developed a novel oral delivery system for GLP-1 medications that protects peptides from stomach acid, potentially eliminating the need for injections.
8 min read
Wegovy Pill Arrives: A New Era for Oral Weight Management in the UAE
Novo Nordisk's revolutionary Wegovy pill (oral semaglutide) is set to transform weight management in the UAE. Discover the details of its early access launch, clinical benefits, and how it integrates into advanced care pathways.
7 min read
Ozempic & Wegovy: Unlocking the Brain's Fading Appetite Signals
A groundbreaking study reveals that the effectiveness of semaglutide, the active ingredient in popular weight loss medications like Ozempic and Wegovy, may be linked to the duration and intensity of chemical signals within specific brain cells. This research sheds light on why weight loss can plateau and offers clues for developing more sustained and effective future therapies.
6 min read
Oral GLP-1s Enter the Ring: Early Trends Favoring Foundao Over Wegovy's Pill
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
6 min read
Wegovy Pill Nears EU Approval: A New Era for Obesity Treatment?
Novo Nordisk's groundbreaking Wegovy pill has received a significant recommendation for approval from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This marks a pivotal step towards potentially broadening access to advanced weight management solutions for adults across the European Union.
6 min read
Retatrutide's Triumph: Lilly's Triple Agonist Redefines Weight Loss Potential
Eli Lilly's retatrutide is making waves in the weight loss landscape. This comprehensive look delves into its Phase III results, comparing it to existing treatments and exploring its potential impact on obesity management.
6 min read
Retatrutide: A New Era in Weight Loss Drugs vs. Ozempic
Eli Lilly's experimental drug retatrutide has demonstrated unprecedented weight loss results in a pivotal trial. This article delves into its mechanisms, efficacy, safety, and how it stacks up against current leading weight loss medications like Ozempic and Wegovy.
6 min read
Michelle Obama's Weight: Addressing Speculation and GLP-1 Rumors
Recent public appearances by Michelle Obama have sparked widespread discussion about her appearance and weight. This article delves into the speculation, explores the role of GLP-1 medications in weight management, and discusses the broader implications of public observation on health and wellness.
6 min read
Beyond Willpower: Understanding Obesity's Metabolic Roots
Obesity is a complex, multi-organ disease, not a failure of willpower. This article delves into its metabolic underpinnings and outlines a practical approach to management, including modern medications and lifestyle adjustments.
7 min read
Oral GLP-1s for Weight Loss Maintenance: A New Frontier
A groundbreaking study reveals that switching to an oral GLP-1 medication like orforglipron can help individuals maintain a significant portion of their weight loss achieved with injectable therapies, offering a new avenue for long-term obesity management.
6 min read
GLP-1 Overdose Leads to Severe Diarrhea: A Warning
A man's harrowing experience with extreme diarrhea after overdosing on an experimental GLP-1 drug, retatrutide, serves as a stark reminder of the risks associated with obtaining and using unapproved medications outside of medical supervision. This article delves into the case, the science behind these powerful weight loss drugs, and the importance of regulated healthcare.
7 min read
GLP-1 Obesity Drugs & Exercise: The Essential Partnership
While GLP-1 agonists offer remarkable weight loss, a new perspective highlights why exercise remains indispensable for long-term success and health benefits, addressing challenges in patient adherence.
7 min read
Online GLP-1 Programs: Revolutionizing Medically Supervised Weight Loss
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
11 min read
GLP-1 Drugs vs. Weight Loss Surgery: A Shifting Landscape
New research indicates a significant decline in bariatric surgeries, coinciding with the rise of GLP-1 medications. This article delves into the implications, comparing the efficacy and cost-effectiveness of these treatments and offering guidance for patients.
7 min read
GLP-1 Supply Chain: How Shaily & Divi's Impact Drug Access
Two Indian firms are quietly powering the global GLP-1 weight loss boom. Learn how their manufacturing roles affect drug availability and therapy consistency.
8 min read
Survodutide Shines: Dual GLP-1/Glucagon Agonist Shows Major Weight Loss
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
7 min read
Mounjaro (Tirzepatide) PBS Listing Fails: Impact on Australian Patients
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
6 min read
Duodenal Resurfacing: A New Hope Beyond GLP-1 Weight Loss?
The emergence of GLP-1 receptor agonists has revolutionized obesity treatment, but concerns about weight regain upon discontinuation are significant. New research on duodenal mucosal resurfacing suggests a potential breakthrough in maintaining weight loss long-term.
7 min read
Dr. Reddy's Semaglutide Inches Closer to Canadian Market Approval
Dr. Reddy's Laboratories has announced a significant milestone in its pursuit of bringing its semaglutide injection to the Canadian market, having received Drug Identification Numbers (DINs) from Health Canada. This development signals progress in the regulatory review process and underscores the company's commitment to expanding access to this important medication.
7 min read
Severe Obesity and Heart Failure: New Insights into Cardiac Muscle Recovery
A groundbreaking Johns Hopkins study reveals that severe obesity causes intrinsic cardiac muscle weakness, but weight loss can trigger significant recovery.
3 min read
Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes
A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.
2 min read
Obesity Drug Coverage Restrictions Force Patients to Pivot
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
5 min read
Amazon Launches GLP-1 Weight Loss Program with Fast Access
Amazon is entering the GLP-1 weight loss market with a new program through One Medical and Amazon Pharmacy, promising fast, convenient access to treatments like Wegovy and Zepbound. With pricing as low as $25/month for insured patients and same-day delivery, it positions weight management as a chronic care solution. This could transform how patients access these popular medications.
5 min read
Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market
While GLP-1R agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) dominate the obesity market, non-GLP-1R targets are poised for explosive growth. Sales for these alternatives are expected to surge almost 50-fold from $310m in 2026 to $15.5bn in 2031, driven by calcitonin receptor drugs. This diversification signals a reshaping of the $172.6bn obesity pharmaceutical landscape by 2031.
5 min read
Indian Companies Rush to Make Generic GLP-1s Like Semaglutide
India's pharma giants are in a fierce race to develop generic GLP-1 drugs like semaglutide following its patent expiry, amid soaring obesity rates affecting nearly a third of adults. One executive dubbed it a 'bloodbath' as demand surges. Eli Lilly's CEO highlighted oral pills as a key solution to global supply shortages.
4 min read
Generic Semaglutide Share Rises to 33% in 10 Days, Boosting Torrent, Dr. Redd...
The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?
5 min read
Inside India's GLP-1 Rush: Generics, Hype, Risks
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
5 min read
Health Canada Warns Against Buying Peptides Online—CBC News Buys Them Easily
Health Canada recently warned Canadians not to buy or use unauthorized injectable peptide drugs amid reports of adverse reactions. Yet CBC News effortlessly purchased three such products online from different sellers. Experts highlight serious risks and contrast them with regulated GLP-1 medications like Ozempic and Wegovy.
5 min read
What the War on Peptides Tells Us About Beauty's Future
Peptides are sweeping social media as injectables for clear skin, muscle gains, and fat loss, but a regulatory crackdown signals a war on unapproved versions. With FDA seizures, RFK Jr.'s advocacy, and black market persistence, what does this mean for beauty's future? Uncover the murky truths behind the hype.
5 min read
India's GLP-1 Opportunity: Startups Betting Big on Weight Loss
With semaglutide's patent expired in India, over 50 generic brands are flooding the market at competitive prices, fueling a five-fold GLP-1 expansion to ₹5,000 crore by 2030. Startups like HealthifyRx, VLCC, Sugarfit, and FITPASS are redefining weight loss with holistic programs combining drugs, coaching, and muscle preservation. Investors warn that only comprehensive care models will thrive amid rising competition.
6 min read
New GLP-1 Playbook for Weight Loss: Shots to Pills Shift
Weight loss treatment is evolving with a new GLP-1 playbook: start with weekly injections for rapid results, then transition to convenient pills for maintenance. Eli Lilly's weight-loss tablet and oral Wegovy promise easier adherence, but with trade-offs in effectiveness and strict dosing rules. Doctors highlight the maintenance challenges that make this shift essential.
6 min read
Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
4 min read
Retatrutide: Can This Shot Aid Weight Loss and Longevity?
Retatrutide, a promising new weight-loss injection, targets three hormone receptors to tackle obesity and diabetes head-on. Clinical trials demonstrate significant weight loss, and experts suggest it may support longevity goals too. Discover how this triple-action therapy stands out in metabolic health.
4 min read
Why Ozempic Doesn't Work for Everyone: Hidden Genetic Reason Found
Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.
5 min read
Genetic Mutations Linked to GLP-1 Drug Weight Loss and Side Effects
New studies uncover genetic variations in GLP1R and GIPR genes that predict better weight loss and higher side effect risks with GLP-1 drugs like Ozempic and Mounjaro. Cardiac protections from semaglutide appear separate from obesity reduction. A mouse study highlights noncoding DNA mutations' profound developmental impacts.
6 min read
Genetic Variations Linked to GLP-1 Weight Loss, Side Effects
New research from 23andMe reveals genetic variants in GLP1R that boost weight loss from GLP-1 drugs by up to 3.3 pounds. GIPR mutations increase vomiting risk on tirzepatide. Meanwhile, semaglutide's heart benefits appear independent of weight loss, opening doors to precision dosing.
5 min read
New Study: Why Ozempic Works Better for Some Due to Genetics
Ozempic and similar weight-loss drugs like tirzepatide work better for some patients due to specific genetic variants affecting GLP-1 and GIP receptors, a new 23andMe study shows. While average users lose 10% body weight, those with certain gene copies shed up to 1.5kg more—or face higher nausea and vomiting risks. This research uncovers why responses vary widely.
5 min read
Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
5 min read
EU Approves Easier Wegovy Delivery, Easing Cold Chain Rules
Novo Nordisk has won EU regulatory approval to ease cold chain requirements for Wegovy injections, marking the first GLP-1 therapy in Europe with such delivery flexibility. The change allows a 48-hour window without refrigeration from pharmacies to patients, streamlining distribution and enhancing access. This aligns with trends in direct-to-patient models and complements recent subscription programs for better affordability.
5 min read
What to Know If Taking Weight Loss Drugs Like Ozempic
Roughly half a million Australians are using GLP-1 weight loss drugs like Ozempic and Mounjaro, with some reporting life-changing results while others face side effects. Professor Kelly Lambert from the University of Wollongong shares key insights on what you need to know. This guide covers mechanisms, safety, and practical tips for users.
5 min read
23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss
A groundbreaking 23andMe study published in Nature identifies specific genetic changes in two genes that predict how well patients respond to GLP-1 drugs for weight loss—and whether they'll experience common side effects like nausea or vomiting. Led by Adam Auton, the research offers proof of concept for genetics in GLP-1 therapy. While experts are intrigued, questions remain on clinical impact.
4 min read
Ozempic Users Warned: Don't Skip Exercise, Study Urges
Ozempic users who skip exercise face suboptimal results, according to a new study in Sports Medicine on GLP-1 drugs like Victoza and Saxenda. Among 193 adults, those combining medication with structured workouts saw the best outcomes, while sedentary users fared worst. Meanwhile, one patient's rare blindness side effect highlights ongoing risks.
5 min read